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Lyme disease test results for >9,000 dogs were col-
lected from participating veterinary clinics. Testing was con-
ducted by using the IDEXX 3Dx kit, used widely by Maine
veterinarians to screen clinically normal dogs during heart-
worm season. This study demonstrates how this test can
be a valuable public health disease surveillance tool.
L
yme disease is the most commonly reported vector-
borne disease in the United States; however, many
experts believe that the number of cases is underreported.
Lyme disease is often regarded as a routine condition or is
frequently managed in high-volume settings (1). Few stud-
ies have assessed the accuracy of passive Lyme disease
surveillance systems, but 1 study showed a 34% reporting
rate (1). When tick identification services are offered, the
identification data can show where disease vectors are
found. In 1989, to determine the extent of the recently rec-
ognized infestation with Ixodes scapularis, the Maine
Medical Center Research Institute’s Vector-borne Disease
Laboratory offered free tick identification to physicians,
hospitals, veterinarians, and the general public. Since that
time, >20,000 ticks, representing 14 species, have been
identified. Testing has documented Borrelia burgorferi
infection in I. scapularis from all Maine counties except 3.
Mapping of ticks submitted for identification is subject
to certain biases, which limits its utility for predicting
human risk. Submission rates vary depending on popula-
tion, education, and local concern, and results show little
about disease transmission, particularly in disease-emer-
gent areas where infection rates may lag behind tick distri-
bution. The limitations of passive Lyme disease
surveillance and tick identification that provide geograph-
ic information about risk can be largely overcome by using
canine seroprevalence studies. Dogs are sensitive indica-
tors because they have greater exposure to ticks. In dis-
ease-endemic areas, >50% of unvaccinated dogs have been
reported to be infected (2,3). The prevalence of Lyme bor-
reliosis in dogs correlates with infection in humans (4,5),
as well as entomologic indicators of disease transmission
(6). A newly available enzyme-linked immunosorbent
assay (ELISA) kit (SNAP 3Dx, IDEXX Laboratories,
Westbrook, ME, USA) is used widely by veterinarians in
Maine to screen dogs for B. burgdorferi and heartworm
infection. This test is used as part of a health screen during
the heartworm testing season and can potentially generate
large volumes of unbiased test data for public health appli-
cation.
The test kit detects antibodies directed against an
invariable region (IR6) of the B. burgdorferi surface pro-
tein VlsE (Vmp-like sequence, Expressed) (2).The C6
ELISAtest is not cross-reactive with antibodies induced by
vaccination with either recombinant B. burdorferi outer-
surface protein A (OspA) or whole-cell bacterin (2). This
test has a very high accuracy rate, with 94.4% sensitivity
and 99.6% specificity reported (7). In a clinical setting,
when 18 dogs with known vaccination history were tested,
the test results were 100% consistent with Western blot
results (8).
The Study
One hundred sixty-four Maine clinics were contacted in
February 2003 and invited to join the study; 69 of these
agreed to participate. Clinics were instructed to record
results of all IDEXX 3Dx Lyme disease tests that were
conducted as part of a routine health screen, to record town
of residence, and to record if a Lyme disease vaccine had
ever been administered. Lyme disease vaccines can be
highly effective (2); however, since vaccination rates are
unevenly distributed, inclusion of vaccinated dogs would
bias estimates of disease risk. This protocol was approved
by the Maine Bureau of Health Institutional Review
Board.
Canine seroprevalence rates were calculated for minor
civil divisions, including towns and unorganized town-
ships. Rates were calculated only for divisions that had
results of 10 or more tests. The relationships between the
canine prevalence rates and human Lyme disease reports to
the Bureau of Health (217 division-matched reports) and
tick submissions to the Vector-borne Disease Laboratory
(12,482 division-matched submissions) for the 2 years
before this study, 2001–2002, were tested with Spearman
rank correlation. Canine C6 antibodies persisted in experi-
mentally infected, untreated dogs for >65 weeks, with no
endpoint described (9); exposure status of the dogs in the
present study could not be determined. Using data from 2
years allowed us to include sufficient numbers of human
reports for meaningful statistic testing without sacrificing
the ability to look at a “snapshot in time” of the Lyme dis-
ease spread. 
Two maps were created. The first map (Figure 1)
showed prevalence rates of minor civil divisions with >10
tests. The second map (Figure 2) showed pooled data from
all divisions, including those with small sample sizes. For
this map, an overlay of the state with 15-minute quadran-
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ed was assigned to the quadrangle that contained the
largest portion of its area. Seroprevalence rates for quad-
rangles were calculated by combining test results from all
divisions within a quadrangle to find the average rate.
Divisions were then assigned the average seroprevalence
rate of their quadrangle for mapping. Quadrangles having
a pooled total of <10 tests were not included in this map.
Test results from 9,511 dogs that had not been vaccinat-
ed for Lyme disease were submitted from 343 minor civil
divisions. Tests were performed from March to July 2003.
The overall seroprevalence rate was 8%. One hundred and
eighty-three divisions met the criterion of a minimum sam-
ple size of 10 for calculating prevalence rates. At the divi-
sion level, seroprevalence rates significantly correlated
with the number of ticks submitted to the Maine Medical
Center Research Institute’s Vector-borne Disease
Laboratory from 2001 to 2002 (r = 0.41, p<0.001), and
human Lyme disease reports to the Bureau of Health (r =
0.15, p<0.05) from 2001 to 2002. 
Regional seroprevalence rates were calculated for 65
quadrangles representing 297 minor civil divisions.
Seroprevalence rates ranged from 0% to 47%. Rates were
highest along southern coastal Maine (<47%), with region-
al rates of 11% as far east as Columbia and along the mid-
New Hampshire border as far north as Upton. Forty-four
divisions with >10 tests had prevalence rates of 0%; 12 of
these had >30 tests and 3 had >60.
Conclusions
This study demonstrates how canine serosurveys using
the IDEXX 3Dx test can serve as an active surveillance
system for potential human Lyme disease risk. This
method overcomes the limitations of human Lyme disease
reporting systems by relying on routine screening of pop-
ulations of healthy dogs to calculate true seroprevalence
rates. In this study, a large volume of data from across the
state was generated for the most extensive and detailed
measure of regional Lyme disease risk in Maine to date. In
contrast, passive human Lyme disease surveillance during
the previous 2 years yields cases from <90 towns, approx-
imately two thirds of which had only 1 or 2 cases. 
Canine seroprevalence rates were congruent with I.
scapularis submissions and human Lyme disease reports
during a 2-year period when dogs could have been infect-
ed, reinforcing the effectiveness of this method for predict-
ing geographic human risk. One previous study has
calculated canine seroprevalence rates in Maine (6), but a
different assay technique was used (4), which limited our
ability to compare those rates to those of the current study.
In spite of substantial agreement between canine sero-
prevalence and rates of tick submissions, mapping of
canine seroprevalence data shows high-risk foci in inland
areas that were not previously identified by 14 years of tick
submissions to the Vector-borne Disease Laboratory or
from human Lyme disease reporting to the Bureau of
Health; this suggests that canine serosurveys may identify
new areas of disease transmission. These are areas of low
human population density, and repeat surveys may demon-
strate the value of canine serosurveillance in detecting dis-
ease spread where human populations are low.
Mapping of pooled data on a regional scale allows geo-
graphic patterns of disease to be viewed. Most notably, our
data show a concentration of infected dogs in southern and
coastal areas. Patterns of infection are suggested in inland
areas as well. The significance of these patterns with
respect to environmental variables favoring disease trans-
mission is unknown but could be clarified by comparing
prevalence rates with patterns of land use, deer herd densi-
ty, habitat, and other ecologic attributes.
The widespread acceptance of the IDEXX 3Dx test
facilitates the use of canine serosurveys for public health. In
many Maine veterinary offices, virtually every dog tested
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Figure 1. Canine Lyme disease seroprevalence rates based on the
IDEXX 3Dx test for minor civil divisions with >10 tests, Maine,
2003.for heartworm in the spring is tested for B. burgdorferi anti-
body; however, well below 100% of canine patients are
vaccinated against Lyme disease. Test results can be col-
lected opportunistically from collaborating veterinarians
with minimal effort. Previous serosurveys have involved
much more intensive effort because of the need for veteri-
narians to collect extra blood samples. The ease of data col-
lection based on this manner of testing enhances real-time
as well as long-term monitoring of disease. Furthermore,
the large volumes of test results generated from routine B.
burgdorferi screening, and the ability to collect information
on dog residence, make large-scale studies of disease geog-
raphy possible. That we did not exclude in our analyses
dogs that have traveled suggests that caution should be used
when considering the importance of low prevalence rates or
prevalence rates calculated from low sample sizes.
However, our finding of dozens of towns with 0% preva-
lence suggests that the effect of dogs that have traveled on
calculated seroprevalence rates is small.
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Figure 2. Regional canine Lyme disease seroprevalence rates cal-
culated from minor civil division pools created within 15-minute
quadrangles, Maine, 2003.
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